Nizatidine, a
histamine H(2)-antagonist, is known to inhibit
acetylcholinesterase (AChE) activity and is used clinically as a gastroprokinetic agent as well as the anti-
ulcer agent. We examined whether or not
nizatidine stimulates duodenal HCO(3)(-) secretion in rats through vagal-
cholinergic mechanisms by inhibiting AChE activity. Under
pentobarbital anesthesia, a proximal duodenal loop was perfused with saline, and the HCO(3)(-) secretion was measured at pH 7.0 using a pH-stat method and by adding 10 mM HCl.
Nizatidine,
neostigmine,
carbachol,
famotidine or
ranitidine was administered i.v. as a single injection.
Intravenous administration of
nizatidine (3-30 mg/kg) dose-dependently increased the HCO(3)(-) secretion, and the effect
at 10 mg/kg was equivalent to that obtained by
carbachol at 0.01 mg/kg. The HCO(3)(-) stimulatory action of
nizatidine was observed at the doses that inhibited the
histamine-induced
acid secretion and enhanced gastric motility. This effect was mimicked by
neostigmine (0.03 mg/kg) and significantly attenuated by bilateral
vagotomy and pretreatment with
atropine but not
indomethacin. The IC(50) of
nizatidine for AChE of rat erythrocytes was 1.4 x 10(-6) M, about 12 times higher than that of
neostigmine.
Ranitidine showed the anti-AchE activity and increased duodenal HCO(3)(-) secretion, similar to
nizatidine, whereas
famotidine had any influence on neither AChE activity nor the HCO(3)(-) secretion. On the other hand, duodenal damage induced by
acid perfusion (100 mM HCl for 4 h) in the presence of
indomethacin was significantly prevented by
nizatidine and
neostigmine, at the doses that increased the HCO(3)(-) secretion. These results suggest that
nizatidine increases HCO(3)(-) secretion in the rat duodenum, mediated by vagal-
cholinergic mechanism, the action being associated with the anti-AChE activity of this agent.